Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Tolvaptan is a vasopressin V(2)-receptor antagonist that has shown promise in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). Tolvaptan was, however, associated with liver injury in some ADPKD patients. Inhibition of bile acid transporters may be contributing factors to drug-induced liver injury. In this study, the ability of tolvaptan and two metabolites, DM-4103 and DM-4107, to inhibit human hepatic transporters (NTCP, BSEP, MRP2, MRP3, and MRP4) and bile acid transport in sandwich-cultured human hepatocytes (SCHH) was explored. IC(50) values were determined for tolvaptan, DM-4103 and DM-4107 inhibition of NTCP (∼41.5, 16.3, and 95.6 μM, respectively), BSEP (31.6, 4.15, and 119 μM, respectively), MRP2 (>50, ∼51.0, and >200 μM, respectively), MRP3 (>50, ∼44.6, and 61.2 μM, respectively), and MRP4 (>50, 4.26, and 37.9 μM, respectively). At the therapeutic dose of tolvaptan (90 mg), DM-4103 exhibited a C(max)/IC(50) value >0.1 for NTCP, BSEP, MRP2, MRP3, and MRP4. Tolvaptan accumulation in SCHH was extensive and not sodium-dependent; intracellular concentrations were ∼500 μM after a 10-min incubation duration with tolvaptan (15 μM). The biliary clearance of taurocholic acid (TCA) decreased by 43% when SCHH were co-incubated with tolvaptan (15 μM) and TCA (2.5 μM). When tolvaptan (15 μM) was co-incubated with 2.5 μM of chenodeoxycholic acid, taurochenodeoxycholic acid, or glycochenodeoxycholic acid in separate studies, the cellular accumulation of these bile acids increased by 1.30-, 1.68-, and 2.16-fold, respectively. Based on these data, inhibition of hepatic bile acid transport may be one of the biological mechanisms underlying tolvaptan-associated liver injury in patients with ADPKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering that mechanisms leading to alterations in bile-acid homeostasis are believed in part to be responsible for recent prominent late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017)”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Slizgi et al. 2016
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics
Hofmann, A. F., & Hagey, L. R. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7568-6 · Cited by 859
Bile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
Enterohepatic bile salt transporters in normal physiology and liver disease
Kullak-ublick, G. A., Stieger, B., & Meier, P. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.06.005 · Cited by 658
Tamai, I., Nezu, J.-I., Uchino, H., Sai, Y., Oku, A., Shimane, M., & Tsuji, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2922 · Cited by 642
Meier, P. J., & Stieger, B. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.082201.100300 · Cited by 586
Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6
Cui, Y., König, J., Leier, I., Buchholz, U., & Keppler, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004968200 · Cited by 515
Research works printed but not linked: 2
- Phillips M. J. Poucell S. Patterson J. Valencia P. (1987). Cholestasis. In The Liver: An Atlas and Text of Ultrastructural Pathology ( Phillips M. J. Poucell S. Patterson J. Valencia P. , Eds.), pp. 101–158. Raven Press, New York.
- Qualyst Transporter Solutions Technical Application Bulletin TAB Biol 005. (2011). TAB Biol 005v2.
Cited by
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“…late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017), there is an increasing need and awareness to better…”
BackgroundRenal Drug Transporters and Drug Interactions
Ivanyuk, A., Livio, F., Biollaz, J., & Buclin, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0506-8 · Cited by 221
Kenna, J. G., Taskar, K. S., Battista, C., Bourdet, D. L., Brouwer, K. L. R., Brouwer, K. R., Dai, D., Funk, C., Hafey, M. J., Lai, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1222 · Cited by 123
Self-citationWoodhead, J. L., Brock, W. J., Roth, S. E., Shoaf, S. E., Brouwer, K. L. R., Church, R. J., Grammatopoulos, T. N., Stiles, L., Siler, S. Q., Howell, B. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw193 · Cited by 96
“Previous research had assessed the potential of tolvaptan, DM-4103, and DM-4107 to inhibit the bile acid transporters BSEP and NTCP (Slizgi et al., 2016).”
InfluentialSelf-citationDrug rechallenge following drug-induced liver injury
Hunt, C. M., Papay, J. I., Stanulovic, V., & Regev, A. (2017) · Hepatology · doi:10.1002/hep.29152 · Cited by 72
“These two compounds are associated with immunoallergic injury (with HLA marker carriage substantively increasing risk of lapatinib liver injury), mitochondrial impairment,(35, 56) and BSEP inhibition.(37, 57) Tolvaptan is a vasopressin V2-receptor antagonist indicated for hyponatremia and evaluated for autosomal domin…”
Woodhead, J. L., Watkins, P. B., Howell, B. A., Siler, S. Q., & Shoda, L. K. M. (2016) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2016.11.008 · Cited by 54
Mosedale, M., Kim, Y., Brock, W. J., Roth, S. E., Wiltshire, T., Eaddy, J. S., Keele, G. R., Corty, R. W., Xie, Y., Valdar, W. S. J., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw269 · Cited by 58
“As susceptible mice in this study had minimal elevations in serum ALT and no histological evidence of liver injury, blood levels of Slpi levels may be elevated in the plasma of patients prior to clinical evidence of tolvaptan DILI.”
BackgroundInfluentialSelf-citationRaschi, E., & De Ponti, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01235 · Cited by 48
Alpers, D., Lewis, J. H., Hunt, C. M., Freston, J. W., Torres, V. E., Li, H., Wang, W., Hoke, M. E., Roth, S. E., Westcott‐Baker, L., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.08.012 · Cited by 48
Sistare, F. D., Mattes, W. B., & LeCluyse, E. L. (2016) · ILAR Journal · doi:10.1093/ilar/ilw025 · Cited by 40
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Bellos, I. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s286952 · Cited by 40
“Experimental evidence has proposed that tolvaptan and its metabolites are able to inhibit multiple bile acid transporters, such as MRP2, BSEP and NTCP leading to altered bile homeostasis.(36) In addition, an ex-situ study in PKC rats, an animal model of ADPKD, demonstrated significantly decreased tolvaptan biliary cle…”
BackgroundHepatic Bile Acid Transporters and Drug-induced Hepatotoxicity
Saran, C., & Brouwer, K. L. R. (2023) · Toxicologic Pathology · doi:10.1177/01926233231212255 · Cited by 30
“As reported by Saran et al, 63 dasatinib, pazopanib and sorafenib showed bile acid-dependent toxicity at clinically relevant concentrations using the C-DILI TM assay with human SCH.”
BackgroundInfluentialSelf-citationHuang, D., Shen, S., Zhuang, Q., Ye, X., Qian, Y., Dong, Z., & Wan, X. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00889-y · Cited by 29
“BAs are secreted into the capillary bile duct of hepatocytes by bile salt export pump (BSEP) and multidrug resistance-associated protein 2 (MRP2) [10].”
BackgroundCao, X., Wang, P., Zhao, W., Yuan, H., Hu, H.-T., Chen, T., Zhang, Y., Ren, Y., Su, L., Fu, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00015 · Cited by 24
Beaudoin, J. J., Brock, W. J., Watkins, P. B., & Brouwer, K. L. R. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2007 · Cited by 22
Self-citationMuto, S., Okada, T., Yasuda, M., Tsubouchi, H., Nakajima, K., & Horie, S. (2017) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s142825 · Cited by 21
“acid transporters by tolvaptan and its metabolites.(12) Further investigation of the mechanism of tolvaptan-induced liver injury might contribute to better clinical management.”
Matsunaga, N., Fukuchi, Y., Imawaka, H., & Tamai, I. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079236 · Cited by 22
Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure
Endo, M., Katayama, K., Matsuo, H., Horiike, S., Nomura, S., Hayashi, A., Ishikawa, E., Harada, T., Sugimoto, R., Tanemura, A., et al. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.09.002 · Cited by 21
Lu, Y., Slizgi, J. R., Brouwer, K. R., Claire, R. L. S., Freeman, K., Pan, M., Brock, W. J., & Brouwer, K. L. R. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067629 · Cited by 20
Self-citationBezençon, J., Beaudoin, J. J., Ito, K., Fu, D., Roth, S. E., Brock, W. J., & Brouwer, K. L. R. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086785 · Cited by 20
Self-citationBeaudoin, J. J., Tiley, J. B., Cao, Y., Mizuno, K., Roth, S. E., Brock, W. J., & Brouwer, K. L. R. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083907 · Cited by 16
Self-citationEvaluation of Drug Biliary Excretion Using Sandwich-Cultured Human Hepatocytes
Fardel, O., Moreau, A., Vée, M. L., Denizot, C., & Parmentier, Y. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0502-x · Cited by 15
Makabe, S., Mochizuki, T., Mitobe, M., Aoyama, Y., Kataoka, H., Tsuchiya, K., & Nitta, K. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1545-7 · Cited by 13
“Recently, it was reported that tolvaptan and its metabolites induce inhibition of bile acid transporters and mitochondrial respiration, which could trigger an idiosyncratic immune response [10, 12, 13].”
BackgroundZhou, L., Pang, X., Jiang, J., Zhong, D., & Chen, X. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074104 · Cited by 13
“Inhibition of bile acid transporters has been implicated in druginduced cholestasis (Stieger et al., 2000; Kostrubsky et al., 2003; Dawson et al., 2012; Li et al., 2015; Slizgi et al., 2016).”
BackgroundMethodInfluentialSafety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
Cao, P., Wang, Q., Wang, Y., Qiao, Q., & Yan, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1509310 · Cited by 11
The management of polycystic liver disease by tolvaptan
Takenaka, T., Miura, S., & Kitajima, M. (2019) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.0026 · Cited by 11
“Although 14 out of 135 ADPKD patients experienced hepatic events in Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) extension Japan trial, they recovered after the interruption of tolvaptan.(11,12) Collectively, our case is consistent with the notion…”
BackgroundA snake toxin as a theranostic agent for the type 2 vasopressin receptor
Droctové, L., Lancien, M., Tran, V. L., Susset, M., Jégo, B., Théodoro, F., Kessler, P., Mourier, G., Robin, P., Diarra, S. S., et al. (2020) · Theranostics · doi:10.7150/thno.47485 · Cited by 17
“Here again, only tolvaptan has reached the market and its use is subject to many concerns [24].”
BackgroundOgimura, E., Tokizono, M., Sekine, S., Nakagawa, T., Bando, K., & Ito, K. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.050 · Cited by 11
In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk
Norona, L. M., Fullerton, A. M., Lawson, C., Leung, L., Brumm, J., Kiyota, T., Maher, J. M., Khojasteh, C., & Proctor, W. R. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02804-4 · Cited by 12
Ali, I., Khalid, S., Stieger, B., & Brouwer, K. L. R. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01124 · Cited by 10
Self-citationUrea transporter UT ‐ A1 as a novel drug target for hyponatremia
Li, N., Zhang, H., Wang, S., Xu, Y. C., Yi, Y., Li, J., Li, X., Li, M., & Yang, B. (2024) · The FASEB Journal · doi:10.1096/fj.202400555rr · Cited by 9
Hoshikawa, K., Naito, T., Saotome, M., Maekawa, Y., & Kawakami, J. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219827045 · Cited by 8
Shoaf, S. E., Bricmont, P., & Gordon, J. R. (2021) · Clinical and Translational Science · doi:10.1111/cts.13017 · Cited by 8
Hoshikawa, K., Naito, T., Akutsu, S., Saotome, M., Maekawa, Y., & Kawakami, J. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13355 · Cited by 7
Gilles, N. (2023) · Biology · doi:10.3390/biology12040544 · Cited by 5
Tiley, J. B., Beaudoin, J. J., Derebail, V. K., Murphy, W. A., Park, C. C., Veeder, J. A., Tran, L., Beers, J. L., Jia, W. P., Stewart, P. W., et al. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16221 · Cited by 5
Self-citationHammond, S., Meng, X., Barber, J., Mosedale, M., Chadwick, A. E., Watkins, P. B., & Naisbitt, D. J. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae142 · Cited by 5
“Slizgi et al. (2016) characterized the inhibitory potential of tolvaptan and its 2 major metabolites on hepatic transporters within sandwich-cultured human hepatocyte cultures in vitro (Table 3).”
InfluentialFardel, O., Moreau, A., Jouan, E., Denizot, C., Vée, M. L., & Parmentier, Y. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2453486 · Cited by 3
“…enzymes, especially cytochromes p -450 and UDP-glucuronosyltransferases, thus permitting to generate drug metabolites and conjugates that may be susceptible to interact with bile acid efflux transporters, as described for metabolites of the vasopressin receptor antagonist tolvaptan [22].”
Tillmann, A. C., Rostami‐Hodjegan, A., Barber, J., & Al‐Majdoub, Z. M. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2501127 · Cited by 3
“A suggested explanation for these liver injuries was the accumulation of bile acids [21,55,56].”
InfluentialLeading-Edge Approaches for In Vitro Hepatotoxicity Evaluation
LeCluyse, E. L., Norona, L. M., Akingbasote, J. A., Howell, L. S., Woodhead, J. L., Cross, M. J., Roth, A. B., & Goldring, C. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64267-8 · Cited by 2
Drug‐Induced Liver Disease: Mechanism and Diagnosis
Stephens, C. M., Lucena, M. I., & Andrade, R. J. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch47 · Cited by 2
Yang, X., Ming, Y., Zhou, Z., Zhou, X., & Rao, C. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04084-0 · Cited by 1
Vaptans: A Narrative Review of Pharmacokinetics, Pharmacogenetics, and Clinical Applications
Lica-Miler, M., Miler, K., Kostrzewa‐Nowak, D., Ciechanowicz, A., Brodkiewicz, A., Różański, J., & Stępniewska, J. (2026) · Cells · doi:10.3390/cells15151388 · Cited by 1
“The predominant metabolite, DM-4103, exhibits no affinity for V2 receptors; however, it possesses hepatotoxic potential [23,24].”
Fontana, S., Belisario, D. C., Giannotta, C., Alessandrì, L., Digiovanni, S., Meoli, A., Passiglia, F., Merlini, A., Palma, G. D., Perin, M., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101462 · Cited by 1
Ma, Y., Yu, M., & Wang, H. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124213 · Cited by 1
Uno, T., Hosomi, K., & Yokoyama, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-77052-y · Cited by 2
Sasaki, R., Kanda, T., Honda, M., Takahashi, H., Kaneko, T., Yamana, Y., Kumagawa, M., Ishii, T., Mizutani, T., Masuzaki, R., et al. (2021) · Kanzo · doi:10.2957/kanzo.62.72 · Cited by 1
Akutsu, S., Mino, Y., Naito, T., Hoshikawa, K., Saotome, M., Maekawa, Y., & Kawakami, J. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03341-y · Cited by 2
“Tolvaptan carboxylic acids potentially cause liver toxicity through the inhibition of hepatic transporters [14].”
BackgroundMechanism‐Based Experimental Models for the Evaluation of BSEP Inhibition and DILI
Murphy, W. A., Saran, C., Honkakoski, P., & Brouwer, K. L. R. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch9 · Cited by 1
Self-citationPotential amelioration of liver function by low-dose tolvaptan in heart failure patients
Mino, Y., Hoshikawa, K., Naito, T., Akutsu, S., Imoto, Y., Nakatsugawa, E., Saotome, M., Maekawa, Y., & Kawakami, J. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102009
“The tolvaptan metabolites DM-4103 and DM-4107 have been recently reported to inhibit human hepatic bile acid transporters [6].”
Huang, D., Shen, S., Zhuang, Q., Ye, X., Qian, Y., Dong, Z., & Wan, X. (2024) · Figshare · doi:10.6084/m9.figshare.25059447
Droctové, L. (2018) · theses.fr (ABES) · doi:10.70675/b0250d67zb6efz41f9z8268z72645c624943 · Cited by 1
Jiang, X., Hu, Y.-X., Cheng, B., Hu, J., Zhao, Y.-Q., Wu, S., Li, H., Gong, L.-M., Feng, G., Li, D., et al. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116113 · Cited by 1
Metadata
- Authors
- Slizgi, J. R., Lu, Y., Brouwer, K. R., St. Claire, R. L., Freeman, K. M., Pan, M., Brock, W. J., & Brouwer, K. L. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Otsuka Pharmaceutical Development & Commercialization, Inc. (United States) (US)
- Corresponding author
- Brouwer, Kim L. R.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10-26
- Volume
- 149
- Issue
- 1
- Pages
- 237-250
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- PMC
- PMC6169477
- OpenAlex
- W2273286870
- Cited by
- 53
- References
- 78
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 5
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Toxicological Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- American Association of Pharmaceutical Scientists
- Otsuka Pharmaceutical
- Otsuka Pharmaceutical Development and Commercialization
- National Institute of General Medical Sciences (R01GM041935)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- tolvaptan, drug-induced liver injury, bile acid transporters, normal tissue complication probability, bile salt export pump, MRP2, MRP3, MRP4, autosomal dominant polycystic kidney disease, hepatotoxicity, taurocholate, chenodeoxycholic acid, biliary excretion
- MeSH terms
- Tolvaptan, Multidrug Resistance-Associated Protein 2, Animals, Benzazepines, Carrier Proteins, Cricetulus, Humans, Membrane Glycoproteins, Taurocholic Acid, CHO Cells, Polycystic Kidney, Autosomal Dominant, Hepatocytes, ATP-Binding Cassette, Sub-Family C Proteins, Chemical and Drug Induced Liver Injury, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.